Aptorum Group and DiamiR Biosciences Announce Two Abstracts Accepted for Presentation at CTAD 2025 Conference

miércoles, 19 de noviembre de 2025, 8:02 am ET1 min de lectura
APM--

DiamiR Biosciences and Aptorum Group announced two poster presentations at the Clinical Trials on Alzheimer's Disease (CTAD) 2025 Conference. The presentations highlight the potential of brain-enriched and inflammation-associated microRNAs as epigenetic biomarkers of neurodegeneration. The studies were funded by the Small Business Innovation Research Grant from the National Institute on Aging. The merger between Aptorum Group and DiamiR Biosciences is expected to close in the first quarter of 2026.

Aptorum Group and DiamiR Biosciences Announce Two Abstracts Accepted for Presentation at CTAD 2025 Conference

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios